• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Elyse Blazevich on Driving Innovation in Colorado's Thriving Life Sciences Ecosystem

Commentary
Video

Sponsored

Elyse Blazevich discusses the Colorado Biosciences Association’s efforts to support the state’s life sciences sector by fostering partnerships, advocating for industry growth, and building a diverse talent pipeline.

Colorado has emerged as a thriving hub for life sciences innovation, with over 720 companies spanning sectors like medical devices, diagnostics, biotech, and pharmaceuticals. In this interview with Pharmaceutical Executive, Elise Blazevich, the CEO and President of the Colorado Biosciences Association, provides a glimpse into the day-to-day operations of the organization, which is dedicated to championing the life sciences industry across the state. Blazevich discusses the association's multifaceted approach, from facilitating access to capital and partnerships to hosting educational and networking events, as well as its work in cultivating a diverse talent pipeline and advocating for the industry at the state and federal levels.

  • 00:23 - Blazevich's background and journey to becoming involved with the Colorado Biosciences Association
  • 02:32 - Day-to-day operations of the Colorado Biosciences Association
  • 03:49 - Overview of the Colorado Life Sciences market, including key sectors and statistics
  • 05:15 - Talent pipeline and recruitment in Colorado
  • 06:11 - Colorado Life Sciences incubation program
  • 07:35 - Fundraising trends and advice for Colorado life sciences companies
  • 09:41 - Role of artificial intelligence and machine learning in the life sciences ecosystem
Recent Videos
Jason Tate, FSP Talent Strategy Lead, PPD, part of Thermo Fisher Scientific
Corevitas Clinical Trials